Merck initiates long-term study on Sotatercept for Pulmonary Arterial Hypertension
Merck is conducting a long-term follow-up study to assess the safety and tolerability of Sotatercept in patients with PAH.
Asset / Drug
Drug and asset intelligence for Sotatercept with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Targeted Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.